Synthesis and structure–activity relationships of heteroaryl substituted-3,4-diamino-3-cyclobut-3-ene-1,2-dione CXCR2/CXCR1 receptor antagonists
摘要:
Comprehensive SAR studies were undertaken in the 3,4-diaminocyclobut-3-ene-1,2-dione class of CXCR2/CXCR1 receptor antagonists to explore the role of the heterocycle on chemokine receptor binding affinities, functional activity, as well as oral exposure in rat. The nature of the heterocycle as well as the requisite substitution pattern around the heterocycle was shown to have a dramatic effect on the overall biological pro. le of this class of compounds. The furyl class, particularly the 4-halo adducts, was found to possess superior binding affinities for both the CXCR2 and CXCR1 receptors, functional activity, as well as oral exposure in rat versus other heterocyclic derivatives. (c) 2008 Elsevier Ltd. All rights reserved.
3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
申请人:Taveras G. Arthur
公开号:US20070021494A1
公开(公告)日:2007-01-25
There are disclosed compounds of the formula
or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.
3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS
申请人:Taveras Arthur G.
公开号:US20090306079A1
公开(公告)日:2009-12-10
There are disclosed compounds of the formula
or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.
3,4-Di-Substituted Cyclobutene-1,2-Diones as CXC-Chemokine Receptor Ligands
申请人:Taveras Arthur G.
公开号:US20110213029A1
公开(公告)日:2011-09-01
There are disclosed compounds of the formula
or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.
3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
申请人:SCHERING CORPORATION
公开号:EP1818325A2
公开(公告)日:2007-08-15
There are disclosed compounds of the formula
or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.